These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 20053769)
1. Structure activity analysis of 2-methoxyestradiol analogues reveals targeting of microtubules as the major mechanism of antiproliferative and proapoptotic activity. Chua YS; Chua YL; Hagen T Mol Cancer Ther; 2010 Jan; 9(1):224-35. PubMed ID: 20053769 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of mitochondrial respiration by the anticancer agent 2-methoxyestradiol. Hagen T; D'Amico G; Quintero M; Palacios-Callender M; Hollis V; Lam F; Moncada S Biochem Biophys Res Commun; 2004 Sep; 322(3):923-9. PubMed ID: 15336552 [TBL] [Abstract][Full Text] [Related]
3. Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. LaVallee TM; Burke PA; Swartz GM; Hamel E; Agoston GE; Shah J; Suwandi L; Hanson AD; Fogler WE; Sidor CF; Treston AM Mol Cancer Ther; 2008 Jun; 7(6):1472-82. PubMed ID: 18566218 [TBL] [Abstract][Full Text] [Related]
4. Mechanism of action of 2-methoxyestradiol: new developments. Mooberry SL Drug Resist Updat; 2003 Dec; 6(6):355-61. PubMed ID: 14744499 [TBL] [Abstract][Full Text] [Related]
5. 2-Methoxyestradiol suppresses microtubule dynamics and arrests mitosis without depolymerizing microtubules. Kamath K; Okouneva T; Larson G; Panda D; Wilson L; Jordan MA Mol Cancer Ther; 2006 Sep; 5(9):2225-33. PubMed ID: 16985056 [TBL] [Abstract][Full Text] [Related]
6. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Mabjeesh NJ; Escuin D; LaVallee TM; Pribluda VS; Swartz GM; Johnson MS; Willard MT; Zhong H; Simons JW; Giannakakou P Cancer Cell; 2003 Apr; 3(4):363-75. PubMed ID: 12726862 [TBL] [Abstract][Full Text] [Related]
7. HIF-1α inhibition by 2-methoxyestradiol induces cell death via activation of the mitochondrial apoptotic pathway in acute myeloid leukemia. Zhe N; Chen S; Zhou Z; Liu P; Lin X; Yu M; Cheng B; Zhang Y; Wang J Cancer Biol Ther; 2016 Jun; 17(6):625-34. PubMed ID: 27082496 [TBL] [Abstract][Full Text] [Related]
8. New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent. Mooberry SL Curr Opin Oncol; 2003 Nov; 15(6):425-30. PubMed ID: 14624224 [TBL] [Abstract][Full Text] [Related]
10. 2-Methoxyestradiol synergizes with sorafenib to suppress hepatocellular carcinoma by simultaneously dysregulating hypoxia-inducible factor-1 and -2. Ma L; Li G; Zhu H; Dong X; Zhao D; Jiang X; Li J; Qiao H; Ni S; Sun X Cancer Lett; 2014 Dec; 355(1):96-105. PubMed ID: 25218350 [TBL] [Abstract][Full Text] [Related]
11. Anticancer drug 2-methoxyestradiol protects against renal ischemia/reperfusion injury by reducing inflammatory cytokines expression. Chen YY; Yeh CH; So EC; Sun DP; Wang LY; Hsing CH Biomed Res Int; 2014; 2014():431524. PubMed ID: 25229058 [TBL] [Abstract][Full Text] [Related]
12. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma. Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651 [TBL] [Abstract][Full Text] [Related]
13. 2ME2 inhibits the activated hypoxia-inducible pathways by cabozantinib and enhances its efficacy against medullary thyroid carcinoma. Lin H; Jiang X; Zhu H; Jiang W; Dong X; Qiao H; Sun X; Jiang H Tumour Biol; 2016 Jan; 37(1):381-91. PubMed ID: 26219898 [TBL] [Abstract][Full Text] [Related]
14. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Escuin D; Kline ER; Giannakakou P Cancer Res; 2005 Oct; 65(19):9021-8. PubMed ID: 16204076 [TBL] [Abstract][Full Text] [Related]
16. Recent Advances in chemistry and pharmacology of 2-methoxyestradiol: An anticancer investigational drug. Kumar BS; Raghuvanshi DS; Hasanain M; Alam S; Sarkar J; Mitra K; Khan F; Negi AS Steroids; 2016 Jun; 110():9-34. PubMed ID: 27020471 [TBL] [Abstract][Full Text] [Related]
17. PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. Muh CR; Joshi S; Singh AR; Kesari S; Durden DL; Makale MT J Neurooncol; 2014 Jan; 116(1):89-97. PubMed ID: 24162827 [TBL] [Abstract][Full Text] [Related]
18. Potentiation of 2-methoxyestradiol-induced cytotoxicity by blocking endothelin A receptor in prostate cancer cells. Mabjeesh NJ; Shefler A; Amir S; Matzkin H Prostate; 2008 May; 68(6):679-89. PubMed ID: 18288682 [TBL] [Abstract][Full Text] [Related]
19. p38 Mitogen-activated protein kinases is required for counteraction of 2-methoxyestradiol to estradiol-stimulated cell proliferation and induction of apoptosis in ovarian carcinoma cells via phosphorylation Bcl-2. Bu SZ; Huang Q; Jiang YM; Min HB; Hou Y; Guo ZY; Wei JF; Wang JW; Ni X; Zheng SS Apoptosis; 2006 Mar; 11(3):413-25. PubMed ID: 16538384 [TBL] [Abstract][Full Text] [Related]
20. Synthesis of 2-alkoxy and 2-benzyloxy analogues of estradiol as anti-breast cancer agents through microtubule stabilization. Sathish Kumar B; Kumar A; Singh J; Hasanain M; Singh A; Fatima K; Yadav DK; Shukla V; Luqman S; Khan F; Chanda D; Sarkar J; Konwar R; Dwivedi A; Negi AS Eur J Med Chem; 2014 Oct; 86():740-51. PubMed ID: 25238172 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]